Document is current

Article History

Received: 4 February 2025

Accepted: 2 June 2025

First Online: 23 June 2025

Declarations

:

: All participants signed an informed consent document. The final protocol, any amendments, and informed consent documentation were reviewed and approved by an Institutional Review Board for each site participating in the study. The study was conducted in accordance with legal and regulatory requirements and followed generally accepted research practices described in the Guidelines for Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology.

: Not applicable.

: The authors declare no competing interests.Supported by Pfizer Hellas SA.PS, IS, IA and DM are employees of Pfizer and may hold stock or stock options. EM, SK, GP, EF, GN, OK, GT, KF, CS, KI, VT, NK, IS, IK, GM, KN, DC, DS, CK, KM, IV, CK, PT and SFN declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.ED reports receiving support from Boehringer and MSD for attending meetings and travels. AG reports receiving consulting fees from Bayer, Servier, Medtronic and Gore. FZ reports participating as principal investigator at Alexandra General Hospital where payments were made to institute and receiving consulting fees, receiving honoraria for lectures and support for attending meetings and travel from AstraZeneca, Daiichi, Eli-Lilly, Merck, Pfizer, Genesis-Pharma, Novartis, MSD, Roche and Gilead. KK reports receiving grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Elpen, GlaxoSmithKline, Menarini and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Elpen, GlaxoSmithKline, Guidotti, Menarini, Pfizer and Sanofi, payment for lectures, presentations, manuscript writing from Alector Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Chiesi, Elpen, Gilead, GlaxoSmithKline, Guidotti, Menarini, Pfizer and Sanofi, participating on a safety data monitoring board or advisory board of Chiesi and being a board member of GOLD Assembly. DS being a board member of Hellenic Angiological Society. HM reports participating at clinical trials of Pfizer, receiving consulting fees from Sanofi and Novartis, honoraria for lectures from Amgen, AstraZeneca, Novartis, Pfizer and Sanofi, support for attending international congresses with travel, accommodation and meeting expenses from Novartis, Sanofi and Vianex and being a board member of Hellenic Society of Atherosclerosis and Hellenic Stroke Organization. TP receiving honoraria for lectures from Pfizer, support for attending international congresses with travel, accommodation and meeting expenses from Pfizer and being general secretary of Hellenic Phlebology Society. FM reports receiving support from Pfizer and Bayer for attending meetings and travels.Disclosure forms provided by the authors are available with the full text of this article at supplementary. No other potential conflict of interest relevant to this article was reported.